Pacific Alternative Asset Management Company Lifted Pampa Energia S A (PAM) Stake By $538,254; Tourbillon Capital Partners LP Has Lowered Alexion Pharmaceuticals (Put) (ALXN) Position

June 12, 2017 - By Peter Erickson

Pacific Alternative Asset Management Company Llc increased Pampa Energia S A (PAM) stake by 113.49% reported in 2016Q4 SEC filing. Pacific Alternative Asset Management Company Llc acquired 15,831 shares as Pampa Energia S A (PAM)’s stock rose 26.59%. The Pacific Alternative Asset Management Company Llc holds 29,780 shares with $1.04 million value, up from 13,949 last quarter. Pampa Energia S A now has $4.66 billion valuation. The stock declined 1.36% or $0.87 reaching $63.07 on the news. About 95,534 shares traded. Pampa Energia S.A. (ADR) (NYSE:PAM) has risen 176.38% since June 12, 2016 and is uptrending. It has outperformed by 159.68% the S&P500.

Tourbillon Capital Partners Lp decreased Alexion Pharmaceuticals Inc (Put) (ALXN) stake by 57.11% reported in 2016Q4 SEC filing. Tourbillon Capital Partners Lp sold 335,604 shares as Alexion Pharmaceuticals Inc (Put) (ALXN)’s stock declined 11.63%. The Tourbillon Capital Partners Lp holds 252,000 shares with $30.83 million value, down from 587,604 last quarter. Alexion Pharmaceuticals Inc (Put) now has $24.54 billion valuation. The stock rose 1.29% or $1.36 reaching $106.74. About 1.34M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since June 12, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Pacific Alternative Asset Management Company Llc decreased Avianca Hldgs Sa (NYSE:AVH) stake by 80,460 shares to 1.16M valued at $11.21M in 2016Q4. It also reduced Spdr S&P 500 Etf Tr (Put) (SPY) stake by 30,553 shares and now owns 205,600 shares. Potash Corp Sask Inc (NYSE:POT) was reduced too.

Investors sentiment is 1.07 in 2016 Q4. Its the same as in 2016Q3. It has no change, as 59 investors sold ALXN shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported. Boothbay Fund Mgmt Limited Liability Corporation accumulated 1,862 shares. Adirondack Tru Comm holds 0.01% or 85 shares. University Of Texas Invest Managment accumulated 0.01% or 40 shares. Sands Capital Management Ltd owns 5.59 million shares for 2.38% of their portfolio. Oakworth Capital Incorporated holds 2,048 shares. Washington Natl Bank owns 17 shares for 0% of their portfolio. Da Davidson & has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 2,887 shares. Intact Inv Management holds 0.03% or 6,600 shares. 1,177 are held by Cornerstone. Bamco Inc reported 20,470 shares. Robeco Institutional Asset Mgmt Bv has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Old Commercial Bank In has 0.09% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 12,196 shares. 160 are held by Edge Wealth Mngmt Ltd Liability Corp. Amp Cap Investors Ltd holds 85,033 shares or 0.06% of its portfolio. Regions Financial stated it has 30,042 shares or 0.05% of all its holdings.

Since January 5, 2017, it had 0 insider buys, and 25 sales for $14.18 million activity. Another trade for 3,570 shares valued at $449,135 was sold by Carmichael Clare. The insider Moriarty John B sold 3,538 shares worth $445,031. Another trade for 2,728 shares valued at $342,904 was sold by MACKAY MARTIN. $206,841 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by O’Neill Julie on Monday, February 27. Shares for $131,357 were sold by Miller Edward on Monday, February 6. On Thursday, January 5 the insider PARVEN ALVIN S sold $3.13M. Shares for $14,499 were sold by BELL LEONARD on Tuesday, January 10.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on July, 27. They expect $1.10 EPS, up 18.28% or $0.17 from last year’s $0.93 per share. ALXN’s profit will be $252.89 million for 24.26 P/E if the $1.10 EPS becomes a reality. After $1.20 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.